Blau Pharmaceutical Has Profit of R $ 69 Million in the 3rd Trio, Decrease of 5%
5 Articles
5 Articles
The profit attributed to the controlling shareholders of Blau Pharmaceuticals amounted to R$ 69.5 million in the third quarter of this year, down 33% compared to the same period of the previous year. In the recurrent metric, the gain was R$ 69 million, down 5% on the annual basis. The company attributed the fall to the high comparison base of the third quarter of 2025, which counted with non-recurring positive impact of the sale of Prothya, a pl…
Blau Pharmaceuticals (BLAU3) had recurring net profit of R$ 69 million in the third quarter, decrease of 5% over the same period last year, according to balance sheet released this Tuesday (10). Without the effects of the exchange rate variation, the recurring profit would have been R$ 79 million, high of 7%, according to the company. The [...]
Blau records revenue advance and profit no 3T26Blau has profit of R$ 79 mi no 3T26 and revenue of R$ 506 mi, with Ebitda of R$ 128 mi
Recurrent Ebitda totaled R$ 128 million, 12% high, with 25.3% margin, 1.2 percentage point expansion
The company's net revenue reached R$ 506 million between July and September, up 7% in the annual comparison
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
